Shares of Praxis Precision Medicines, Inc. (PRAX) surged 14.56% during intraday trading on Thursday, driven by better-than-expected second-quarter financial results and encouraging regulatory advancements for its late-stage central nervous system (CNS) pipeline.

The company reported a net loss of $2.87 per share, significantly beating the consensus analyst estimate of a $3.65 loss. The narrower loss came alongside a strengthened balance sheet, with $1.4 billion in cash, cash equivalents and marketable securities, which is expected to fund operations into 2028. The earnings beat and robust cash position gave investors confidence in the company's ability to execute its commercial plans.

Investor sentiment was further lifted by a series of positive FDA updates. Mid-cycle meetings for ulixacaltamide (essential tremor) and relutrigine (SCN2A and SCN8A developmental and epileptic encephalopathies) were completed successfully, with no major safety or efficacy concerns to date and no advisory committee meetings planned. Bioresearch Monitoring inspections concluded with no Form 483 observations. Additionally, Praxis received its third Breakthrough Therapy Designation for elsunersen, underscoring the company's leadership in CNS precision medicine. With commercial launch preparations accelerating for potential near-term approvals, the stock rallied sharply.